海普瑞，主力打压,利好越来越近，有钱的买。

最近主动打压：天道公司，英文名称:Techdow

http://www.ema.europa.eu/ema/index.jsp?
curl=pages/medicines/human/medicines/004264/smops/Positive/human_smop_001009.jsp&mid=WC0b01ac058001d127

-----------------------------------------------------------------------------------------------------------------------
On 21 July 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for themedicinal product Inhixa, intended for prevention and treatment of various disorders related to blood clots in adults. The applicant for this medicinal product is Techdow Europe AB.
Inhixa will be available as a solution for injection [2,000 IU (20 mg) in 0.2 mL, 4,000 IU (40 mg) in 0.4 mL, 6,000 IU (60 mg) in 0.6 mL, 8,000 IU (80 mg) in 0.8 mL and 10,000 IU (100 mg) in 1 mL]. The active substance of Inhixa is enoxaparin sodium, an antithrombotic agent (ATC code: B01AB05). Enoxaparin sodium is a low-molecular weight heparin that has a high activity against the blood clotting factor Xa and a low anti-factor IIa or antithrombin activity.